The 9 new FIGHT KIDS CANCER research programs selected in 2023
You have been looking forward to them... Discover the research programs we will be running for in September - selected by ImagineForMargo.
In 2023, 37 research projects were evaluated according to three criteria - patient impact, scientific excellence and innovation. 9 of them were selected and will receive funding from Imagine for Margo, as well as KickCancer, Kriibskrank Kanner, the Cris Foundation and the KiKa Foundation.
This year, research programs which will receive funding by Imagine for Margo will focus on brain tumors, Hodgkin's lymphoma, glioma, leukemia and Ewing's sarcoma.
* PATOI: A PROMISING NEW THERAPEUTIC STRATEGY AGAINST BRAIN TUMORS
- Project duration: 2 years
- Lead institution: Gustave Roussy Institute, France
- Principal investigator: Dr. Samuel Abbou
- Participating countries: Austria, Denmark, France, Germany, Italy, Netherlands, Spain, United Kingdom
EURHOLY: A EUROPEAN PROJECT TO CURE MORE AND BETTER PEDIATRIC HODGKIN LYMPHOMA
- Project duration: 3 years
- Lead institution: Armand Trousseau Hospital, Sorbonne University, France
- Principal investigator: Dr. Mathieu Simonin
- Participating institutions and countries: Henri Becquerel Cancer Center, France / Justus Liebieg-University of Giessen, Germany
MEDULLODRUGS: FINDING NEW TREATMENTS IN MEDULLOBLASTOMAS
- Project duration: 3 years
- Field: Translational project on Medulloblastoma
- Main institution: University of Trento, Italy
- Principal Investigator: Dr. Luca Tiberi
- Participating institutions and countries: Institut Curie, France
EPITARGET-KIDS: A PROGRAM TO REVEAL THE VULNERABILITIES OF INFILTRATING BRAINSTEM GLIOMA
- Project duration: 2 years
- Main institution: International Agency for Research on Cancer (IARC), France
- Principal investigator: Dr. Rita Khoueiry
- Participating institutions and countries: Cancer Research Center of Lyon, France / University of Strasbourg, France / Research Center for Molecular Medicine of the Austrian Academy of Sciences, Austria
ATG4TALL: A PRECLINICAL TESTING PLATFORM TO IMPROVE THE TREATMENT OF RESISTANT T-TYPE ACUTE LYMPHOBLASTIC LEUKEMIA
- Project duration: 2 years
- Lead institution: Princess Maxima Center for Pediatric Oncology, The Netherlands
- Principal Investigator: Dr. Frank van Leeuwen
- Participating institutions and countries: University of Glasgow, UK / University of Newcastle, UK / UCL Cancer Institute, UK / University Medical Center Hamburg Eppendorf, Germany / University of Lisbon, Portugal / APHP, France / University College Dublin, Ireland / Umea University, Sweden / University of Ghent, Belgium
* ENCOURAGE: A PROJECT TO EXPLORE THE CELLULAR ORIGINS OF THERAPEUTIC FAILURE IN PEDIATRIC GLIOMAS IN ORDER TO OPTIMIZE TARGETED THERAPIES
- Project duration: 2 years
- Lead institution: University Children’s Hospital Zürich, Switzerland
- Principal investigator: Dr Ana Guerreiro Stücklin
- Participating institutions and countries: Institut Curie, France
SKELETAL LATE EFFECTS: UNDERSTANDING AND PREVENTING THE SIDE EFFECTS OF RADIATION THERAPY
- Project duration: 2 years
- Lead institution: Karolinska Institut, Sweden
- Principal Investigator: Dr. Phillip Newton
- Participating institutions and countries: Lausanne University Hospital, Switzerland
* REMODELING: MODULATION OF THE TUMOR IMMUNE ENVIRONMENT IN HIGH-GRADE PEDIATRIC GLIOMAS, THROUGH TARGETED DRUG DELIVERY TO THE TUMOR VIA ULTRASOUND
- Project duration: 2 years
- Lead institution: Princess Maxima Center for Pediatric Oncology, The Netherlands
- Principal Investigator: Dr. John Bianco
- Participating institutions and countries: Leiden University Medical Center, The Netherlands
BIOESMART: CONFIRMING THE POTENTIAL OF A TREATMENT FOR EWING’S SARCOMA
- Project duration: 2 years
- Lead institution: CHU Bordeaux, France
- Principal investigator: Dr Jordane Chaix
- Participating institutions and countries: Institut Gustave Roussy, France / Institut Curie, France / University Children’s Hospital Zürich, Switzerland
English 
Français